Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Vaccine
Killed Mycobacterium vaccae may augment efficacy of trastuzumab
March 24th, 2005
Killed Mycobacterium vaccae may augment the efficacy of trastuzumab in metastatic breast cancer patients. "SRL172, non-specific immunological adjuvant downregulates interleukin (IL)-4, upregulates IL-2 production, switching towards a T-helper-1 response, induces an increase in natural killer cells and activates antigen presenting cells. The human epidermal growth factor receptor 2 gene amplification is frequently observed in a number of primary tumors, suggesting that the overexpression of this growth factor receptor may contribute to transformation and tumorigenesis. Gene amplification occurs in {{approx}}15-20% of human breast cancers. Amplification is...
Source: Women's Health Weekly (2005-03-24)
|
